Mac‐2 binding protein glycosylation isomer predicts tolerability and clinical outcome of lenvatinib therapy for hepatocellular carcinoma

2021 ◽  
Author(s):  
Yuji Eso ◽  
Shigeharu Nakano ◽  
Masako Mishima ◽  
Soichi Arasawa ◽  
Eriko Iguchi ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Clinical Outcome ◽  
Binding Protein ◽  
Protein Glycosylation

scholarly journals Mac-2 Binding Protein Glycosylation Isomer as a Hepatocellular Carcinoma Marker in Patients With Chronic Hepatitis B or C Infection

2019 ◽  
Vol 3 (4) ◽  
pp. 493-503 ◽  
Author(s):  
Tomi Jun ◽  
Yao-Chun Hsu ◽  
Shintaro Ogawa ◽  
Yen-Tsung Huang ◽  
Ming-Lun Yeh ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Chronic Hepatitis ◽  
Hepatitis B ◽  
Chronic Hepatitis B ◽  
Binding Protein ◽  
Protein Glycosylation

Serum Mac‐2‐binding protein glycosylation isomer and risk of hepatocellular carcinoma in entecavir‐treated chronic hepatitis B patients

2019 ◽  
Vol 34 (10) ◽  
pp. 1817-1823 ◽  
Author(s):  
Lung‐Yi Mak ◽  
Michael Ko ◽  
Elvis To ◽  
Danny Ka‐Ho Wong ◽  
Justin Hei‐Chun Ma ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Chronic Hepatitis ◽  
Hepatitis B ◽  
Chronic Hepatitis B ◽  
Binding Protein ◽  
Protein Glycosylation

scholarly journals Usefulness of Mac-2 Binding Protein Glycosylation Isomer for Prediction of Posthepatectomy Liver Failure in Patients With Hepatocellular Carcinoma

2017 ◽  
Vol 265 (6) ◽  
pp. 1201-1208 ◽  
Author(s):  
Yukihiro Okuda ◽  
Kojiro Taura ◽  
Kenji Yoshino ◽  
Yoshinobu Ikeno ◽  
Takahiro Nishio ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Liver Failure ◽  
Binding Protein ◽  
Protein Glycosylation ◽  
Posthepatectomy Liver Failure

Serum Mac-2-Binding Protein Glycosylation Isomer at Virological Remission Predicts Hepatocellular Carcinoma and Death in Chronic Hepatitis B-Related Cirrhosis

2019 ◽  
Author(s):  
Tung-Hung Su ◽  
Cheng-Yuan Peng ◽  
Tai-Chung Tseng ◽  
Hung-Chih Yang ◽  
Chun-Jen Liu ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Chronic Hepatitis ◽  
Hepatitis B ◽  
Antiviral Therapy ◽  
Chronic Hepatitis B ◽  
Binding Protein ◽  
Cox Proportional Hazards ◽  
Protein Glycosylation ◽  
Derivation Cohort ◽  
The Mean

Abstract Background To investigate serum Mac-2-binding protein glycosylation isomer (M2BPGi) levels in predicting hepatocellular carcinoma (HCC) and mortality at virological remission (VR, HBV DNA <20 IU/mL) following antiviral therapy in chronic hepatitis B (CHB) patients with cirrhosis. Methods This retrospective cohort study included patients with CHB-related Child-Pugh A cirrhosis undergoing long-term antiviral therapy. Serum M2BPGi levels were quantified and multivariable Cox proportional hazards regression models were used to identify risk predictors for HCC and death. Results A total of 126 and 145 patients were included in the derivation and validation cohorts, respectively. The mean age was 56, and the mean M2BPGi level was 1.86 cut-off index (COI) in the derivation cohort. After adjustment for confounders, a higher M2BPGi level at VR significantly predicted HCC (hazard ratio [HR]: 1.58, 95% confidence interval [CI]: 1.19-2.10, P=0.002) and death (HR: 2.17, 95% CI: 1.02-4.62, P=0.044). The M2BPGi ³3 COI significantly increased the risk of HCC and death in the derivation and validation cohorts. Serial M2BPGi levels declined significantly (P=0.0001) in non-HCC patients only, and remained significantly lower than those who developed HCC afterwards (P=0.039). Conclusions Serum M2BPGi levels at antiviral therapy-induced VR predict HCC development and death in patients with CHB-related Child-Pugh A cirrhosis.

scholarly journals Combination of Mac-2 Binding Protein Glycosylation Isomer and Up-To-Seven Criteria as a Useful Predictor for Child-Pugh Grade Deterioration after Transarterial Chemoembolization for Hepatocellular Carcinoma

Cancers ◽  
2019 ◽  
Vol 11 (3) ◽  
pp. 405 ◽  
Author(s):  
Yuji Eso ◽  
Atsushi Takai ◽  
Ken Takahashi ◽  
Yoshihide Ueda ◽  
Kojiro Taura ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Transarterial Chemoembolization ◽  
Time Window ◽  
Binding Protein ◽  
Surrogate Marker ◽  
Intermediate Stage ◽  
Protein Glycosylation ◽  
Factors Associated ◽  
Treatment Switch ◽  
One Year

Transarterial chemoembolization (TACE) is the recommended first-line treatment for intermediate-stage hepatocellular carcinoma (HCC). In patients who became refractory to TACE, a treatment switch to tyrosine kinase inhibitors (TKIs) needs to be considered. However, TACE could worsen liver function, thereby narrowing the time window for a switch to TKIs because TKIs are recommended for patients with Child-Pugh grade A (CP-A). We investigated the factors associated with CP grade deterioration after TACE. Among patients who underwent TACE, 125 patients with CP-A were enrolled. The cumulative CP grade deterioration rates were 20.3%, 27.1%, and 41.4% at six months, one year, and two years, respectively. Multivariate analysis revealed that factors associated with CP grade deterioration included high Mac-2 binding protein glycosylation isomer (M2BPGi) levels (>2.00 cut-off index) and beyond the up-to-seven criteria. The cumulative CP grade deterioration rates of patients with high M2BPGi and beyond the up-to-seven criteria were 50.6% and 59.2% at six months and one year, respectively, which were significantly higher than for those in any other groups. The combination of M2BPGi and up-to-seven criteria could be a surrogate marker for predicting CP grade deterioration after TACE. In patients with intermediate-stage HCC, elevated M2BPGi levels, and beyond the up-to-seven criteria, an early treatment switch to TKIs should be considered to improve their prognosis.

Sign in / Sign up

Export Citation Format

Share Document